Website profile

Quiver Quantitative

quiverquant.com
All articles Clear site filter
  • 1,304articles · 30d
  • 15+ hour agolatest article
  • Aug 15, 2026earliest in window
  • 0%with images
  • 303avg words
articles per day
Covers
People
Places
Organizations
Categories
  • News 796
  • Economy, Business & Finance 743
  • Finance & Business 622
  • Politics 617
  • Politics2 530
  • Finance 216
  • Business & Industrial 88
  • Health & Wellness 87
Bylines

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Quiver Quantitative
quiverquant.com > news > Eisai+and+Biogen+Announce+China+Approval+of+LEQEMBI+SC-AI+for+Initiation+Treatment+of+Early+Alzheimer%E2%80%99s+Disease

Eisai and Biogen Announce China Approval of LEQEMBI SC-AI for Initiation Treatment of Early Alzheimer’s Disease | BIIB Stock News

1+ week, 4+ day ago   (472+ words) LEQEMBI SC-AI approved in China for early Alzheimer's treatment, offering at-home administration options and reduced healthcare resource needs. LEQEMBI SC-AI is a subcutaneous autoinjector formulation of lecanemab, approved for treating mild cognitive impairment due to Alzheimer's disease. LEQEMBI SC-AI was…...

Quiver Quantitative
quiverquant.com > news > Eisai+and+Biogen+Announce+Canada%E2%80%99s+Drug+Agency+Final+Recommendation+Supporting+Public+Reimbursement+of+LEQEMBI+for+Eligible+Early+Alzheimer%E2%80%99s+Disease+Patients

Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients | BIIB Stock News

1+ week, 6+ day ago   (456+ words) Canada's Drug Agency recommends public reimbursement for LEQEMBI® in eligible Alzheimer’s patients, advancing access in Canada. LEQEMBI® is a monoclonal antibody designed to treat mild cognitive impairment or mild dementia due to Alzheimer’s disease. Canada’s Drug Agency (CDA-AMC) issued the…...

Google News
quiverquant.com > news > Emergent+BioSolutions+Awarded+Canadian+Government+Standing+Offer+for+NARCAN+Nasal+Spray

Emergent BioSolutions Awarded Canadian Government Standing Offer for NARCAN Nasal Spray

2+ week, 2+ hour ago   (471+ words) Emergent BioSolutions will supply NARCAN® Nasal Spray to Canadian government entities through a new standing offer until 2029. The standing offer expands access to opioid overdose emergency treatment across Canada, supporting timely access to life-saving medication in communities. The standing offer…...

Quiver Quantitative
quiverquant.com > news > Emergent+BioSolutions+Expands+Ready+to+Rescue+Campaign+on+U.S.+Campuses+and+in+Canada+for+International+Overdose+Awareness+Day

Emergent BioSolutions Expands Ready to Rescue Campaign on U.S. Campuses and in Canada for International Overdose Awareness Day | EBS Stock News

2+ week, 2+ hour ago   (344+ words) Emergent BioSolutions' Ready to Rescue campaign promotes opioid overdose awareness and preparedness at U.S. colleges through partnerships and education. The Ready to Rescue campaign raises awareness about opioid overdose preparedness and encourages carrying NARCAN® Nasal Spray on college campuses. The campaign…...